Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CHPT stock price vs LRCX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LRCX's multiple
Needs LRCX P/S.
Implied fair value · at CHPT's multiple
Needs CHPT P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CHPT FY 2026 (ended Jan 31, 2026) · LRCX FY 2026 (ended Jun 28, 2026). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ChargePoint Holdings, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
LAM RESEARCH CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
12.25x
0.30x
Net debt / EBITDA
Leverage against operating earnings
-0.74x
-0.21x
Cash and equivalents
Liquid reserves on the balance sheet
$141.56M
$5.58B
Total debt
Interest-bearing obligations outstanding
$260.85M
$3.72B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CHPT can meaningfully improve growth, margins, and solvency rather than simply re-rate to LRCX’s much stronger business model, then hold or add selectively; otherwise, avoid assuming LRCX-based upside is realistic because the valuation gap is dominated by major fundamental differences.
CHPT trades at $5.46 versus an LRCX-derived implied price of $334.77, implying 6031.3% upside on the provided P/S framework. However, that gap is explained by the fact that CHPT’s revenue base, margins, and growth are far below LRCX’s, so LRCX multiple is not supported by comparable fundamentals.
Supporting Metrics
